79 related articles for article (PubMed ID: 18217270)
1. Exit Exubera. Inhalable insulin is withdrawn due to weak sales.
Keegan A
Diabetes Forecast; 2007 Dec; 60(13):19. PubMed ID: 18217270
[No Abstract] [Full Text] [Related]
2. What went wrong? A retrospective on Exubera.
Baran MK; Godoy AT
Adv Nurse Pract; 2008 Nov; 16(11):53-4, 77. PubMed ID: 19999057
[No Abstract] [Full Text] [Related]
3. Inhaled insulin: gone with the wind?
Mathieu C; Gale EA
Diabetologia; 2008 Jan; 51(1):1-5. PubMed ID: 18026925
[No Abstract] [Full Text] [Related]
4. Inhaled insulin--does it become reality?
Siekmeier R; Scheuch G
J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():81-113. PubMed ID: 19218634
[TBL] [Abstract][Full Text] [Related]
5. Pfizer dumps Exubera.
Mack GS
Nat Biotechnol; 2007 Dec; 25(12):1331-2. PubMed ID: 18066009
[No Abstract] [Full Text] [Related]
6. Inhaled insulin no longer marketed: discontinuation. Welcome news.
Prescrire Int; 2008 Aug; 17(96):139. PubMed ID: 19480094
[TBL] [Abstract][Full Text] [Related]
7. First inhalable insulin approved.
Katsnelson A
Nat Biotechnol; 2006 Apr; 24(4):369-70. PubMed ID: 16601705
[No Abstract] [Full Text] [Related]
8. NICE says no to inhaled insulin: what lessons should we learn?
Freemantle N
Pharmacoeconomics; 2006; 24(7):627-9. PubMed ID: 16802838
[No Abstract] [Full Text] [Related]
9. Sanofi to propel inhalable insulin Afrezza into market.
Kling J
Nat Biotechnol; 2014 Sep; 32(9):851-2. PubMed ID: 25203014
[No Abstract] [Full Text] [Related]
10. Identifying factors that affect patients' willingness to pay for inhaled insulin.
Pinto SL; Holiday-Goodman M; Black CD; Lesch D
Res Social Adm Pharm; 2009 Sep; 5(3):253-61. PubMed ID: 19733826
[TBL] [Abstract][Full Text] [Related]
11. Insulin for oral inhalation (Exubera).
Dinman S
Plast Surg Nurs; 2007; 27(2):117-8. PubMed ID: 17565311
[No Abstract] [Full Text] [Related]
12. With bated breath, companies await approval for inhalable drugs.
Dolgin E
Nat Med; 2012 Feb; 18(2):183. PubMed ID: 22310668
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: A 3-year randomized controlled trial.
Skyler JS; Hollander PA; Jovanovic L; Klioze S; Krasner A; Riese RJ; Reis J; Schwartz P; Duggan W;
Diabetes Res Clin Pract; 2008 Nov; 82(2):238-46. PubMed ID: 18824271
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceuticals and medical devices: FDA oversight.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
[No Abstract] [Full Text] [Related]
15. U-100 insulin proposed as single strength available.
FDA Drug Bull; 1978; 8(5):32. PubMed ID: 700292
[No Abstract] [Full Text] [Related]
16. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557
[No Abstract] [Full Text] [Related]
17. Approval of purified insulins.
FDA Drug Bull; 1980 Nov; 10(3):21-2. PubMed ID: 7004974
[No Abstract] [Full Text] [Related]
18. Another inhaled insulin casualty.
Aldridge S
Nat Biotechnol; 2008 Mar; 26(3):255. PubMed ID: 18327221
[No Abstract] [Full Text] [Related]
19. Insulin-micro- and nanoparticles for pulmonary delivery.
Klingler C; Müller BW; Steckel H
Int J Pharm; 2009 Jul; 377(1-2):173-9. PubMed ID: 19446621
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of insulin analogs.
Brixner DI; McAdam-Marx C
Am J Manag Care; 2008 Nov; 14(11):766-75. PubMed ID: 18999911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
